Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06806046 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 11, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. 2 versions Re-verified since May 21, 2026, no change to tracked fieldsv10-v11
  2. Primary and study completion pushed from May 7, 2026 to Sep 30, 2026v9
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 24 to confirmed 12 · Site details revised at 3 of 3 sites · Study title expanded, about 1 wordv8 Show 3 more changesShow less
    • Enrollment target: estimated 24 to confirmed 12
    • Site details revised at 3 of 3 sites
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. 3 versions Re-verified since Aug 25, 2025, no change to tracked fieldsv5-v7
  5. Primary completion date: May 25, 2026 to May 7, 2026 Completion date: Aug 7, 2026 to May 7, 2026v4 Show 1 more changeShow less
    • Completion date: Aug 7, 2026 to May 7, 2026
  6. 2 versions Re-verified since May 2, 2025, no change to tracked fieldsv2-v3
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck KGaA
43 trials monitored
See 4 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
The purpose of this study is to evaluate the safety and early clinical activity of M9140 in Chinese participants with locally advanced or metastatic colorectal cancer (CRC).
Trial Details
NCT Number NCT06806046
Lead Sponsor Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Solid Tumors, Colorectal Cancer
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov